Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin

Approved

Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin is one of 8 therapeutic programs targeting Rhegmatogenous Retinal Detachment. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Rhegmatogenous Retinal DetachmentRecruiting

Rhegmatogenous Retinal DetachmentApproved

Recruiting

Competition

Competitive Landscape

14 competitors in Rhegmatogenous Retinal Detachment

#DrugCompanyPhaseTrials

Actigall

AbbVie

Approved

—2

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 3

Denufosol Tetrasodium (INS37217)

Merck & Co.

Phase 2

1 4

Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin

MMassachusetts Eye and Ear Infirmary

Approved

1 5

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Phase 1

1 6

Intravitreal Topotecan

UUnity Health Toronto

Phase 2

1 7

ONL1204

OONL Therapeutics

Phase 1

1 8

Sulfur Hexafluoride

TTurku University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

ApprovedRecruiting

Rhegmatogenous Retinal Detachment

NCT05331664

Clinical

Trials by Indication[1]

Rhegmatogenous Retinal Detachment1 trial

Dropless Pars Plana Vitrectomy Study

Recruiting·MMassachusetts Eye and Ear Infirmary·Approved·NCT05331664·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Massachusetts Eye and Ear Infirmary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: MMassachusetts Eye and Ear Infirmary

Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Rhegmatogenous Retinal Detachment1 trial

References

Drug Info

Quick Facts

Related News